产品货号

CP002

产品规格

1mg

反应种属

Mouse

克隆号

RMP1-14-CP002

同种型

Mouse IgG1(switched from rat IgG2a)

免疫原

Syrian Hamster BKH cells transfected with mouse PD-1 cDNA

实验应用

in vivo blocking of PD-1/PD-L signaling*

*Reported for the original rat IgG2a RMP1-14 antibody

产品形式

PBS, pH 7.0,Contains no stabilizers or preservatives

纯度

>95%, Determined by SDS-PAGE

聚合

<5%, Determined by SEC

无菌处理

0.2 µm filtration

纯化方式

Protein G

分子量

150 kDa

小鼠病原检测

Ectromelia/Mousepox Virus: Negative

Hantavirus: Negative

K Virus: Negative

Lactate Dehydrogenase-Elevating Virus: Negative

Lymphocytic Choriomeningitis virus: Negative

Mouse Adenovirus: Negative

Mouse Cytomegalovirus: Negative

Mouse Hepatitis Virus: Negative

Mouse Minute Virus: Negative

Mouse Norovirus: Negative

Mouse Parvovirus: Negative

Mouse Rotavirus: Negative

Mycoplasma Pulmonis: Negative

Pneumonia Virus of Mice: Negative

Polyoma Virus: Negative

Reovirus Screen: Negative

Sendai Virus: Negative

Theiler’s Murine Encephalomyelitis: Negative

保存条件

抗体原液保存在4°C，不能冷冻保存。

推荐抗体稀释液

InVivoPure pH 7.0 Dilution Buffer（货号IP0070）

体内PD-1/PD-L信号阻断

(in vivo blocking of PD-1/PD-L 

signaling)

1. Triplett, T. A., et al. (2018). 'Reversal of indoleamine 2,3-dioxygenase-mediated cancer 

immune suppression by systemic kynurenine depletion with a therapeutic enzyme' Nat 

Biotechnol 36(8): 758-764.

2. Grasselly, C., et al. (2018). 'The Antitumor Activity of Combinations of Cytotoxic 

Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent' Front Immunol 9: 2100.

3. Moynihan, K. D., et al. (2016). 'Eradication of large established tumors in mice by 

combination immunotherapy that engages innate and adaptive immune responses' Nat 

Med. doi : 10.1038/nm.4200.

4. Ngiow, S. F., et al. (2015). 'A Threshold Level of Intratumor CD8+ T-cell PD1 Expression 

Dictates Therapeutic Response to Anti-PD1' Cancer Res 75(18): 3800-3811.  

5. Evans, E. E., et al. (2015). 'Antibody Blockade of Semaphorin 4D Promotes Immune 

Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies' 

Cancer Immunol Res 3(6): 689-701.

6. Zelenay, S., et al. (2015). 'Cyclooxygenase-Dependent Tumor Growth through Evasion 

of Immunity' Cell 162(6): 1257-1270.

7. Zander, R. A., et al. (2015). 'PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk 

Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity' Cell 

Host Microbe 17(5): 628-641.